01
“The biggest change wasn’t the scale.”
Participant 1847
26 weeks recorded
Independent observational research · GLP-3 is investigational and not FDA-approved
R3TA
Beyond the Clinical Studies, It's the Human Stories.
R3TA is an independent observational research platform built to collect, organize, and analyze the human stories behind GLP-3 — tracking changes in weight, appetite, body composition, energy, side effects, lifestyle and more.
Why now
GLP-3 could represent the next chapter in metabolic medicine.
24.2%
Mean weight reduction at 48 weeks reported in the published Phase 2 study.
28.3%
Average weight loss at 80 weeks at the 12 mg dose reported in the Phase 3 TRIUMPH-1 trial.
Q1 2027
The FDA submission Lilly has said it plans for GLP-3.
But averages aren’t individuals. Clinical trials tell us what happened in the trial. R3TA wants to understand the human stories behind those numbers.
The big question
What actually happens over 26 weeks?
Day 1
01
Week 4
02
Week 8
03
Week 12
04
Week 24
05
Week 26
06
At each stage, R3TA collects standardized self-reported measures across five areas of the human story.
Weight & body
Weight, waist circumference, body composition if available, clothing size and physical changes.
Hunger & food
Appetite, cravings, food noise, satiety, meal size and food preferences.
Daily life
Energy, sleep, mood, concentration, exercise and perceived quality of life.
Side effects
Nausea, constipation, diarrhoea, vomiting, reflux, fatigue, skin sensitivity and other reported events.
Treatment context
Duration, reported dose/titration history, previous GLP-1/GIP therapy and discontinuation — recording what someone reports, never recommending a regimen.
Contributors
—
Active contributors
—
Observations
—
Open cohorts
—
Published reports
—
Live counters from the R3TA database — never estimated. Cells under 5 contributors are suppressed in aggregate views.
Why R3TA exists
An observational registry, stated plainly.
What we do
We run a longitudinal observational registry. Contributors record their own measurements on a fixed cadence, and we structure, de-identify, and analyse those records — we never direct, supply, or prescribe anything.
What we measure
Weight, waist circumference, appetite and satiety, energy, sleep, activity, blood pressure, body composition, optional third-party labs, and every reported symptom or safety event.
Our goal
To turn scattered anecdote into structured evidence: transparent cohort definitions, declared evidence tiers, published attrition, and aggregates only once at least five contributors are represented.
Our hypothesis
That standardised, prospectively collected self-report — anchored to a fixed baseline and paired with source-verified measurements — can describe real-world trajectories that isolated testimonials cannot.
5 minutes. Once a week.
6 months of insight.
Join the research →Your story becomes more valuable when it becomes data. Participation is voluntary, versioned, and revocable at any time.
How tracking works
One baseline. A continuous thread of change.
R3TA tracks each contributor from a single anchored baseline and follows the change over weeks — not isolated snapshots. The curve below is compiled from real contributor stories; every point reports how many contributors it represents.
Longitudinal tracking
Mean change from baseline
Weight Waist
Computing aggregates…
Tracking method
Anchored, continuous, verifiable.
- 01
Anchor a baseline
First measurement locks the reference point. Every later value is tracked as change from this anchor.
- 02
Record on cadence
Weekly and monthly check-ins append to the same longitudinal thread — each timestamped and source-stamped.
- 03
Verify the source
Self-reported entries are distinguished from device- and lab-verified values, so trust can be stratified.
- 04
Aggregate with privacy
Cells under 5 contributors are suppressed. Published curves always report sample size per point.
Cohort composition
Who the registry actually represents.
Computing aggregates…
Structured · Standardized · Source-stamped
What the registry collects
Every story carries a source, a collection method, and a verification state. Aggregate cells with fewer than 5 contributors are suppressed before publication.
Weekly check-ins
01Weight, waist, energy, appetite, sleep, and GI tolerability — recorded on a fixed weekly cadence.
Monthly check-ins
02Blood pressure, resting heart rate, and structured side-effect review every month.
Laboratory panel
03Optional third-party lab documents every 8–12 weeks, stored with verification state.
Wearable device data
04Steps, HRV, and sleep exports from contributor devices, flagged by source.
Demographics & baseline
05Age band, sex, and activity level captured once at enrollment for cohort stratification.
Safety reports
06Structured adverse-event reports, reviewed and counted in aggregate only.
Clinical research vs R3TA
Different data. Different purpose.
Clinical trials
R3TA
Controlled environment
Observational environment
Defined enrollment criteria
Broader self-selected population
Investigator measured
Primarily self-reported
Controlled protocols
Records reported stories
Establish safety and efficacy
Identify real-world patterns
Scientific endpoints
Story-focused endpoints
Both can teach us something. R3TA never implies that its dataset proves GLP-3 is safe or effective — the compound remains investigational.
Evidence tiers
Transparent evidence, ranked.
Every R3TA report declares an evidence level so readers can judge the strength of a finding at a glance — from individual story through source-verified registry analysis to formally governed clinical studies.
E0
E0 — Anecdotal
Single unverified self-report with no standardized collection or follow-up.
Lowest tier. Illustrative only.
E1
E1 — Structured self-report
Standardized definitions, units, and cadence collected prospectively in the registry.
Usable for descriptive trends with stated limitations.
E2
E2 — Registry analysis
Pre-specified cohort analysis of longitudinal registry data with attrition and missing-data reporting.
Primary tier for R3TA research reports.
E3
E3 — Source-verified registry analysis
Registry analysis restricted to third-party laboratory or connected-device measurements.
Highest observational tier.
E4
E4 — Governed clinical study
Formally governed prospective study with protocol, principal investigator, and ethics oversight.
Highest R3TA evidence tier.
Laboratory markers · mean change, first to latest
Computing aggregates…
Scope & boundaries
Observe. Record. Never prescribe.
R3TA is strictly observational. We do not assign, recommend, or direct the use of any compound, and we do not provide medical advice. Interventional studies require a principal investigator, IRB approval, and regulatory oversight — separate from this registry.
Community
Why contributors take part.
Personal accounts from people who chose to record structured measurements for the registry. These are stories, not evidence of outcomes.
02
“I didn’t realize how much I thought about food until I stopped thinking about it.”
Participant 2051
36 weeks recorded
03
“My first month was completely different from my third.”
Participant 1732
24 weeks recorded
Grow the registry
Invite a storyteller
Aggregate cohort charts stay suppressed until at least five contributors submit longitudinal measurements. Share a signup link with someone whose story could add to the picture.
Sign in to send tracked invites and see which ones get opened.
Contact
Send us a message.
Questions about the registry, participation, or data access? We typically respond within 24 hours.
Registry updates.
New cohorts, publications, and data releases from the R3TA registry.